CardioExchange Archive

July 28th, 2014

Selections from Richard Lehman’s Literature Review: July 28th

Richard Lehman, BM, BCh, MRCGP

This week’s topics include a comparison of catheter-directed thrombolysis plus anticoagulation and anticoagulation alone to treat DVT, several papers on dabigatran and bleeding risk, and more.

---

February 3rd, 2014

Intensive BP, Lipid Lowering Does Not Protect Against Cognitive Decline in Diabetics

Nicholas Downing, MD

Intensive treatment of blood pressure or cholesterol does not slow the rate of cognitive decline in adults with type 2 diabetes, according to a substudy of the ACCORD trial published in JAMA Internal Medicine. Some 3000 older adults with poorly controlled diabetes, high cardiovascular risk, and no evidence of cognitive impairment were assigned to one of […]

---

August 24th, 2012

Is Bad News About Fibrates Getting Buried?

Harlan M. Krumholz, MD, SM

A meta-analysis about lipid-modifying therapies and risk for pancreatitis focuses on a benefit of statins but de-emphasizes potential harm from fibrates.

---

August 10th, 2011

Rethinking Trilipix — And the Process for Approving Lipid-Modifying Drugs

Sanjay Kaul, MD

Editor’s Note: In an article published in the New England Journal of Medicine, three members of the FDA’s Endocrinologic and Metabolic Drugs Advisory Committee (Allison Goldfine, Sanjay Kaul, and William Hiatt) offer their perspective on the May 19 committee meeting to review the controversial ACCORD-Lipid Study. Here, one of those authors, Sanjay Kaul, provides his […]

---

May 17th, 2011

FDA Reviewers Scrutinize ACCORD and Trilipix

Larry Husten, PHD

The FDA has released the agenda, questions, roster, and briefing materials for Thursday’s meeting of the Endocrinologic and Metabolic Drugs Advisory Committee in which the ACCORD trial and the fate of Abbott’s Trilipix (fenofibric acid) will be discussed. The key questions on which the advisory committee members will be asked to vote are: Should the FDA require […]

---

April 26th, 2011

FDA Briefs: New Stent Approved, Advisory Committee Meeting on ACCORD Lipid

Larry Husten, PHD

Boston Scientific said on Monday that it had received FDA approval for a third-generation drug-eluting stent, the ION Paclitaxel-Eluting Platinum Chromium Coronary Stent System. The “unique platinum chromium (PtCr) alloy” is specifically designed for use in the coronary arteries. The FDA announced that the Endocrinologic and Metabolic Drugs Advisory Committee would meet on May 19 to […]

---